Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01555983 · ClinicalTrials.gov registry record · Phase 2

Vaporized Cannabis and Spinal Cord Injury Pain

A Phase 2 study of Spinal Cord Injuries and Spinal Cord Diseases, sponsored by Barth Wilsey.

Completed
Registry status
Phase 2
Development phase
42
Enrollment target
1
Study location

NCT01555983 is a Phase 2 study of Spinal Cord Injuries and Spinal Cord Diseases that has completed, run by Barth Wilsey. The registered enrollment target is 42 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01555983, a Phase 2 study of Spinal Cord Injuries and Spinal Cord Diseases, has completed, sponsored by Barth Wilsey.

COMPLETED
Registry status
Phase 2
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.

Interventions

  • DRUG Vaporization of Cannabis

Study Locations (1)

California

  • UC Davis CTSC Clinical Research Center , Sacramento VA Medical Center - Mather

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2012-07
Est. Completion 2014-08
Phase Phase 2

Sponsor

Barth Wilsey

1 total trials

What the Registry Record Tells You About NCT01555983

The ClinicalTrials.gov registry entry for NCT01555983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (31% lower). The listed sponsor is Barth Wilsey, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which Vaporization of Cannabis is the first listed.

NCT01555983 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01555983 about?

NCT01555983 is a clinical study titled "Vaporized Cannabis and Spinal Cord Injury Pain". This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will al...

What is the current status of trial NCT01555983?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-07. Estimated completion is 2014-08.

What conditions does trial NCT01555983 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Spinal Cord Diseases.

What interventions are being tested in trial NCT01555983?

The interventions under investigation include: Vaporization of Cannabis (DRUG).

Who is sponsoring clinical trial NCT01555983?

This trial is sponsored by Barth Wilsey, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01555983 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.